Orphazyme: Summary of 2018, important year ahead

Research Update

2019-03-04

07:30

Arimoclomol in the NPC indication will drive the story in the near-term but Orphazyme has a broad pipeline with multiple potential value drivers in the longer term. In this update we go through the recent news items and look ahead at the next steps for the company.

MS

Mathias Spinnars

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.